UNICYCIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
UNICYCIVE THERAPEUTICS, INC. (UNCY) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $7.51 million as of 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2025-11-12
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $7.51M.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $5.41M.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $189.00K.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $705.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2025-09-30 | $7.51M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $5.41M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $189.00K 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $705.00K 10-Q · filed 2025-11-12 | |
| 2024-09-30 | $81.00K 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $48.00K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $6.01M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $1.20M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $35.25M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $102.86M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $229.07M 10-Q · filed 2023-05-16 | |
| 2022-12-31 | $52.00K 10-K · filed 2024-03-28 | |
| 2022-03-31 | $172.00K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $321.00K 10-Q · filed 2022-05-12 | $321.00 10-K · filed 2022-03-31 |
| 2021-09-30 | $504.00 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $2.63K 10-Q · filed 2021-08-16 | |
| 2020-12-31 | $2.20K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |